A New Clinical Pathway for Personalized Management of Borderline Resectable and Locally Advanced Pancreatic Cancer (NORPACT-3)
A New Clinical Pathway for Personalized Management of Borderline Resectable and Locally Advanced Pancreatic Cancer - Norwegian Pancreatic Cancer Trial-3 (NORPACT 3)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Knut Jørgen Labori, MD PhD
- Phone Number: +4723070000
- Email: uxknab@ous-hf.no
Study Contact Backup
- Name: Jacob Ghotbi, MD
- Phone Number: +4723070000
- Email: Jacob.Ghotbi@ous-hf.no
Study Locations
-
-
-
Bergen, Norway, 5021
- Not yet recruiting
- Haukeland University Hospital
-
Contact:
- Jon-Helge Angelsen, MD PhD
- Phone Number: +47 55 97 50 00
- Email: jon-helge.angelsen@helse-bergen.no
-
Oslo, Norway, 0424
- Recruiting
- Oslo University Hospital
-
Contact:
- Jacob Ghotbi, MD
- Phone Number: +4723070000
- Email: Jacob.Ghotbi@ous-hf.no
-
Contact:
- Knut J Labori, MD PhD
- Phone Number: +4723070000
- Email: uxknab@ous-hf.no
-
Stavanger, Norway, 4068
- Not yet recruiting
- Stavanger University Hospital
-
Contact:
- Kjetil Søreide, MD PhD
- Phone Number: +47 51 51 80 00
- Email: kjetil.soreide@uib.no
-
Tromsø, Norway, 9038
- Not yet recruiting
- University Hospital of North Norway
-
Contact:
- Linn S Nymo, MD PhD
- Phone Number: +47 77 62 60 00
- Email: Linn.Save.Nymo@unn.no
-
Trondheim, Norway, 7006
- Not yet recruiting
- St. Olavs Hospital, Trondheim University Hospital
-
Contact:
- Erling A Bringeland, MD PhD
- Phone Number: +47 72 57 30 00
- Email: Erling.Audun.Bringeland@stolav.no
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Borderline resectable or locally advanced adenocarcinoma of the pancreas (NCCN, version 2, 2021) (Appendix 3)
- Nx, M0 (UICC 8th version, 2016)
- Cytological or histological confirmation of adenocarcinoma
- Age >18 year
- Considered able to receive primary chemotherapy and possible surgery
- Written informed consent
Exclusion Criteria:
- Co-morbidity or performance status precluding primary chemotherapy
- Co-morbidity or performance status precluding pancreatectomy
- Female patients in child-bearing age not using adequate contraception, pregnant or lactating women
- Mental or physical disorders that could interfere with treatment of with the provision of informed consent
- Any reason why, in the opinion of the investigator, the patient should not participate
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Resection rate (of the pancreatic tumour)
Time Frame: From November 2024-December 2027
|
Resection rate: National target of 50% in BRPC and 15% in LAPC in patients initiating primary chemotherapy.
|
From November 2024-December 2027
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Overall survival
Time Frame: From November 2024-December 2027
|
After resection, median overall survival of 24 months, 1 year survival 80%, and 5 year survival >20%.
|
From November 2024-December 2027
|
|
Mortality after surgical resection
Time Frame: From November 2024-December 2027
|
90-day postoperative mortality ≤5%
|
From November 2024-December 2027
|
|
Morbidity after surgical resection
Time Frame: From November 2024-December 2027
|
90-day postoperative major morbidity (Clavien-Dindo ≥ grade3) of ≤40%
|
From November 2024-December 2027
|
|
Number of patients evaluated at national MDT undergoing resection
Time Frame: From November 2024-December 2027
|
From November 2024-December 2027
|
|
|
Adverse events
Time Frame: From November 2023-December 2027
|
Adverse events during primary chemotherapy
|
From November 2023-December 2027
|
|
R0 resection rate
Time Frame: From November 2023-December 2027
|
R0 (microscopic radical resection >1mm) versus R1 (microscopic residual tumor ≤1mm).
|
From November 2023-December 2027
|
|
Quality of life EORTC QLQ-C30
Time Frame: Measured at baseline, 3, 6, and 12 months from diagnosis, followed by yearly measurements.]
|
Outcome measures will be calculated, according to the validated questionnaire manuals.
|
Measured at baseline, 3, 6, and 12 months from diagnosis, followed by yearly measurements.]
|
|
Quality of life EORTC QLQ-PAN26
Time Frame: Measured at baseline, 3, 6, and 12 months from diagnosis, followed by yearly measurements.
|
Outcome measures will be calculated, according to the validated questionnaire manuals.
|
Measured at baseline, 3, 6, and 12 months from diagnosis, followed by yearly measurements.
|
|
Quality of life EQ-5D-5L
Time Frame: Measured at baseline, 3, 6, and 12 months from diagnosis, followed by yearly measurements.
|
Outcome measures will be calculated, according to the validated questionnaire manuals.
|
Measured at baseline, 3, 6, and 12 months from diagnosis, followed by yearly measurements.
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
PET CT
Time Frame: From November 2023-December 2027
|
|
From November 2023-December 2027
|
|
Molecular profiling (KRAS mutation status, MSI) at time of diagnosis
Time Frame: From November 2023-December 2027
|
|
From November 2023-December 2027
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Publications and helpful links
General Publications
- Springfeld C, Ferrone CR, Katz MHG, Philip PA, Hong TS, Hackert T, Buchler MW, Neoptolemos J. Neoadjuvant therapy for pancreatic cancer. Nat Rev Clin Oncol. 2023 May;20(5):318-337. doi: 10.1038/s41571-023-00746-1. Epub 2023 Mar 17.
- Farnes I, Kleive D, Verbeke CS, Aabakken L, Issa-Epe A, Smastuen MC, Fosby BV, Dueland S, Line PD, Labori KJ. Resection rates and intention-to-treat outcomes in borderline and locally advanced pancreatic cancer: real-world data from a population-based, prospective cohort study (NORPACT-2). BJS Open. 2023 Nov 1;7(6):zrad137. doi: 10.1093/bjsopen/zrad137.
- Boggi U, Kauffmann EF, Napoli N, Barreto SG, Besselink MG, Fusai GK, Hackert T, Hilal MA, Marchegiani G, Salvia R, Shrikhande SV, Truty M, Werner J, Wolfgang C, Bannone E, Capretti G, Cattelani A, Coppola A, Cucchetti A, De Sio D, Di Dato A, Di Meo G, Fiorillo C, Gianfaldoni C, Ginesini M, Hidalgo Salinas C, Lai Q, Miccoli M, Montorsi R, Pagnanelli M, Poli A, Ricci C, Sucameli F, Tamburrino D, Viti V, Cameron J, Clavien PA, Asbun HJ; REDISCOVER guidelines group. REDISCOVER guidelines for borderline-resectable and locally advanced pancreatic cancer: management algorithm, unanswered questions, and future perspectives. Updates Surg. 2024 Sep;76(5):1573-1591. doi: 10.1007/s13304-024-01860-0. Epub 2024 Apr 29.
- Stoop TF, Theijse RT, Seelen LWF, Groot Koerkamp B, van Eijck CHJ, Wolfgang CL, van Tienhoven G, van Santvoort HC, Molenaar IQ, Wilmink JW, Del Chiaro M, Katz MHG, Hackert T, Besselink MG; International Collaborative Group on Locally Advanced Pancreatic Cancer. Preoperative chemotherapy, radiotherapy and surgical decision-making in patients with borderline resectable and locally advanced pancreatic cancer. Nat Rev Gastroenterol Hepatol. 2024 Feb;21(2):101-124. doi: 10.1038/s41575-023-00856-2. Epub 2023 Nov 30.
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- REK sør-øst D 733339
- 2023010 (Other Grant/Funding Number: Southern and Eastern Norway Regional Health Authority)
- 279530-2023 (Other Grant/Funding Number: Norwegian Cancer Society)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.